Antibody Contract Manufacturing Market Report and Forecast 2025-2034
Description
The global antibody contract manufacturing market was valued at USD 18.17 Billion in 2024, driven by the rising incidence of chronic diseases across the globe. The market is anticipated to grow at a CAGR of 12.20% during the forecast period of 2025-2034, with the values likely to reach USD 57.45 Billion by 2034.
Antibody Contract Manufacturing Market Overview
Antibody contract manufacturing involves the production of biologic therapies, including monoclonal antibodies (mAb), polyclonal antibodies, and others. These therapeutics target specific antigens to treat cancer, autoimmune disorders, and infectious diseases. With advancements in mAbs, bispecific antibodies, and antibody-drug conjugates (ADCs), the market is poised for substantial growth in the forecast period.
Antibody Contract Manufacturing Market Growth Drivers
Rising Prevalence of Chronic Diseases is Likely to Drives Market Growth
According to the Centers for Disease Control and Prevention (CDC) 2024 report, approximately 129 million people in the United States (including children and adults) are affected by one or more major chronic illnesses including heart disease, cancer, diabetes, obesity, and hypertension illnesses. The rising prevalence of chronic diseases is driving market demand for antibody contract manufacturing as the need for effective therapeutic alternatives against chronic diseases is on the rise.
Antibody Contract Manufacturing Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Surge in FDA Approvals to Boost Market Growth
In June 2023, UCB's RYSTIGGO® (rozanolixizumab-noli) received FDA approval under the Priority Review designation. This humanized IgG4 monoclonal antibody eliminates the symptoms of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. The market is witnessing a surge in drug approvals that involve monoclonal antibodies. This can be attributed to the increasing adoption of these therapies for treating and managing rare and chronic diseases. This, in turn, is boosting the demand for antibody contract manufacturing.
Rising Preference for Monoclonal Antibodies (mAbs)
Monoclonal antibodies are gaining preference due to their targeted approach and effectiveness in treating various diseases, particularly in oncology and autoimmune disorders. Their ability to target specific substances helps reduce side effects, contributing to their appeal in targeted treatments.
Growing Demand for Bispecific Antibodies to Boost the Antibody Contract Manufacturing Market Demand
Bispecific antibodies, designed to bind to two distinct antigens simultaneously, are gaining traction in the market due to their ability to provide dual-action therapeutic benefits. They are especially effective in treating complex diseases, such as cancer, and are opening new possibilities in antibody design and advanced treatments, thereby accelerating the demand for antibody contract manufacturing.
Adoption of Antibody-Drug Conjugates (ADCs) for Cancer Treatment to Boost Antibody Contract Manufacturing Market Value
Antibody-drug conjugates (ADCs) are transforming cancer treatment by directly delivering potent drugs to tumor cells, minimizing harm to normal tissues, and improving treatment efficacy. This precision is revolutionizing cancer treatment, positioning ADCs as a key focus area in the market.
Antibody Contract Manufacturing Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
Market Segmentation Based on the Product is Anticipated to Witness Substantial Growth
Based on product, the market is divided into monoclonal antibodies, polyclonal antibodies, and others. Among these, the monoclonal antibody segment leads the market share due to its extensive applications in oncology, immunology, and therapies for autoimmune conditions. The market share for targeted therapies is expected to grow further as its adoption witnesses an increase and biotechnology advances.
Antibody Contract Manufacturing Market Analysis by Region
Regionally, the market report offers an insight into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Among these, North America is expected to dominate the market because of the presence of major pharmaceutical companies and substantial healthcare expenditures. Intensive research efforts and government support for cancer research are fueling the expansion of the domestic market.
Leading Players in the Antibody Contract Manufacturing Market
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Lonza
Founded in 1897, this company is headquartered in Basel, Switzerland, it is one of the largest companies providing a wide range of antibody contract manufacturing services, with a focus on monoclonal antibody production. Some of their products include Darzalex® (daratumumab), and Avastin (bevacizumab), among others. The company offers mammalian cell culture technologies, process development, and commercial manufacturing on an industrial scale.
Thermo Fisher Scientific Inc.
Founded in 2006, Thermo Fisher Scientific is based in Waltham, Massachusetts, USA. The company offers a broad range of services in antibody contract manufacturing and produces antibodies like Repatha® (evolocumab) and Imfinzi® (durvalumab). Thermo Fisher supports the biopharma industry with its integrated services, including antibody production, purification, and final formulation.
WuXi Biologics (Cayman) Inc.
Founded in 2010 and headquartered in Wuxi, China, they have produced antibodies like Imfinzi® (durvalumab) and Bavencio® (avelumab). WuXi offers services ranging from the development of the cell line to commercial-scale antibody production for global markets throughout Europe, North America, and the rest of the world.
FUJIFILM Holdings Corporation
FUJIFILM Holdings is a leading company in the manufacture of antibody contract services, established in 1934 and headquartered in Tokyo, Japan. Their products include Opdivo (nivolumab) and Yervoy (ipilimumab). Other services involved in the market include biologics and commercial-scale production of monoclonal antibodies.
Other companies include Samsung Biologics Co., Ltd., Charles River Laboratories, AGC Biologics, Cytovance Biologics, Inc., Emergent BioSolutions, Labcorp Drug Development, Catalent, Inc., and Boehringer Ingelheim Biopharmaceuticals GmbH.
Key Questions Answered in the Global Antibody Contract Manufacturing Market
Antibody Contract Manufacturing Market Overview
Antibody contract manufacturing involves the production of biologic therapies, including monoclonal antibodies (mAb), polyclonal antibodies, and others. These therapeutics target specific antigens to treat cancer, autoimmune disorders, and infectious diseases. With advancements in mAbs, bispecific antibodies, and antibody-drug conjugates (ADCs), the market is poised for substantial growth in the forecast period.
Antibody Contract Manufacturing Market Growth Drivers
Rising Prevalence of Chronic Diseases is Likely to Drives Market Growth
According to the Centers for Disease Control and Prevention (CDC) 2024 report, approximately 129 million people in the United States (including children and adults) are affected by one or more major chronic illnesses including heart disease, cancer, diabetes, obesity, and hypertension illnesses. The rising prevalence of chronic diseases is driving market demand for antibody contract manufacturing as the need for effective therapeutic alternatives against chronic diseases is on the rise.
Antibody Contract Manufacturing Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Surge in FDA Approvals to Boost Market Growth
In June 2023, UCB's RYSTIGGO® (rozanolixizumab-noli) received FDA approval under the Priority Review designation. This humanized IgG4 monoclonal antibody eliminates the symptoms of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. The market is witnessing a surge in drug approvals that involve monoclonal antibodies. This can be attributed to the increasing adoption of these therapies for treating and managing rare and chronic diseases. This, in turn, is boosting the demand for antibody contract manufacturing.
Rising Preference for Monoclonal Antibodies (mAbs)
Monoclonal antibodies are gaining preference due to their targeted approach and effectiveness in treating various diseases, particularly in oncology and autoimmune disorders. Their ability to target specific substances helps reduce side effects, contributing to their appeal in targeted treatments.
Growing Demand for Bispecific Antibodies to Boost the Antibody Contract Manufacturing Market Demand
Bispecific antibodies, designed to bind to two distinct antigens simultaneously, are gaining traction in the market due to their ability to provide dual-action therapeutic benefits. They are especially effective in treating complex diseases, such as cancer, and are opening new possibilities in antibody design and advanced treatments, thereby accelerating the demand for antibody contract manufacturing.
Adoption of Antibody-Drug Conjugates (ADCs) for Cancer Treatment to Boost Antibody Contract Manufacturing Market Value
Antibody-drug conjugates (ADCs) are transforming cancer treatment by directly delivering potent drugs to tumor cells, minimizing harm to normal tissues, and improving treatment efficacy. This precision is revolutionizing cancer treatment, positioning ADCs as a key focus area in the market.
Antibody Contract Manufacturing Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
- Monoclonal Antibodies
- Polyclonal Antibodies
- Others
- Mammalian
- Microbial
- Cardiology
- Oncology
- Infectious Diseases
- Immune Disorders
- Neurology
- Others
- Biopharmaceutical and Pharmaceutical Companies
- Research Laboratories
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Market Segmentation Based on the Product is Anticipated to Witness Substantial Growth
Based on product, the market is divided into monoclonal antibodies, polyclonal antibodies, and others. Among these, the monoclonal antibody segment leads the market share due to its extensive applications in oncology, immunology, and therapies for autoimmune conditions. The market share for targeted therapies is expected to grow further as its adoption witnesses an increase and biotechnology advances.
Antibody Contract Manufacturing Market Analysis by Region
Regionally, the market report offers an insight into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Among these, North America is expected to dominate the market because of the presence of major pharmaceutical companies and substantial healthcare expenditures. Intensive research efforts and government support for cancer research are fueling the expansion of the domestic market.
Leading Players in the Antibody Contract Manufacturing Market
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Lonza
Founded in 1897, this company is headquartered in Basel, Switzerland, it is one of the largest companies providing a wide range of antibody contract manufacturing services, with a focus on monoclonal antibody production. Some of their products include Darzalex® (daratumumab), and Avastin (bevacizumab), among others. The company offers mammalian cell culture technologies, process development, and commercial manufacturing on an industrial scale.
Thermo Fisher Scientific Inc.
Founded in 2006, Thermo Fisher Scientific is based in Waltham, Massachusetts, USA. The company offers a broad range of services in antibody contract manufacturing and produces antibodies like Repatha® (evolocumab) and Imfinzi® (durvalumab). Thermo Fisher supports the biopharma industry with its integrated services, including antibody production, purification, and final formulation.
WuXi Biologics (Cayman) Inc.
Founded in 2010 and headquartered in Wuxi, China, they have produced antibodies like Imfinzi® (durvalumab) and Bavencio® (avelumab). WuXi offers services ranging from the development of the cell line to commercial-scale antibody production for global markets throughout Europe, North America, and the rest of the world.
FUJIFILM Holdings Corporation
FUJIFILM Holdings is a leading company in the manufacture of antibody contract services, established in 1934 and headquartered in Tokyo, Japan. Their products include Opdivo (nivolumab) and Yervoy (ipilimumab). Other services involved in the market include biologics and commercial-scale production of monoclonal antibodies.
Other companies include Samsung Biologics Co., Ltd., Charles River Laboratories, AGC Biologics, Cytovance Biologics, Inc., Emergent BioSolutions, Labcorp Drug Development, Catalent, Inc., and Boehringer Ingelheim Biopharmaceuticals GmbH.
Key Questions Answered in the Global Antibody Contract Manufacturing Market
- What was the global antibody contract manufacturing market value in 2024?
- What is the global antibody contract manufacturing market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the product?
- What is the market breakup based on the source?
- What is the market segmentation based on therapeutic area?
- What is the market segmentation based on the end user?
- What are the major factors aiding the antibody contract manufacturing market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major antibody contract manufacturing market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the antibody contract manufacturing market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- Which indication dominates the antibody contract manufacturing market?
- How is the Asia Pacific region contributing to the growth of the antibody contract manufacturing market?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Antibody Contract Manufacturing Market Overview
- 3.1 Global Antibody Contract Manufacturing Market Historical Value (2018-2024)
- 3.2 Global Antibody Contract Manufacturing Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Antibody Contract Manufacturing Market Landscape*
- 5.1 Global Antibody Contract Manufacturing Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Antibody Contract Manufacturing Market: Product Landscape
- 5.2.1 Analysis by Product
- 5.2.2 Analysis by Source
- 5.2.3 Analysis by Therapeutic Area
- 6 Global Antibody Contract Manufacturing Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Antibody Contract Manufacturing Market Segmentation (218-2034)
- 7.1 Global Antibody Contract Manufacturing Market (2018-2034) by Product
- 7.1.1 Market Overview
- 7.1.2 Monoclonal Antibodies
- 7.1.3 Polyclonal Antibodies
- 7.1.4 Others
- 7.2 Global Antibody Contract Manufacturing Market (2018-2034) by Source
- 7.2.1 Market Overview
- 7.2.2 Mammalian
- 7.2.3 Microbial
- 7.3 Global Antibody Contract Manufacturing Market (2018-2034) by Therapeutic Area
- 7.3.1 Market Overview
- 7.3.2 Cardiology
- 7.3.3 Oncology
- 7.3.4 Infectious Diseases
- 7.3.5 Immune Disorders
- 7.3.6 Neurology
- 7.3.7 Others
- 7.4 Global Antibody Contract Manufacturing Market (2018-2034) by End User
- 7.4.1 Market Overview
- 7.4.2 Biopharmaceutical and Pharmaceutical Companies
- 7.4.3 Research Laboratories
- 7.4.4 Others
- 7.5 Global Antibody Contract Manufacturing Market (2018-2034) by Region
- 7.5.1 Market Overview
- 7.5.2 North America
- 7.5.3 Europe
- 7.5.4 Asia Pacific
- 7.5.5 Latin America
- 7.5.6 Middle East and Africa
- 8 North America Antibody Contract Manufacturing Market (218-2034)
- 8.1 North America Antibody Contract Manufacturing Market (2018-2034) by Product
- 8.1.1 Market Overview
- 8.1.2 Monoclonal Antibodies
- 8.1.3 Polyclonal Antibodies
- 8.1.4 Others
- 8.2 North America Antibody Contract Manufacturing Market (2018-2034) by Source
- 8.2.1 Market Overview
- 8.2.2 Mammalian
- 8.2.3 Microbial
- 8.3 North America Antibody Contract Manufacturing Market (2018-2034) by Therapeutic Area
- 8.3.1 Market Overview
- 8.3.2 Cardiology
- 8.3.3 Oncology
- 8.3.4 Infectious Diseases
- 8.3.5 Immune Disorders
- 8.3.6 Neurology
- 8.3.7 Others
- 8.4 North America Antibody Contract Manufacturing Market (2018-2034) by End User
- 8.4.1 Market Overview
- 8.4.2 Biopharmaceutical and Pharmaceutical Companies
- 8.4.3 Research Laboratories
- 8.4.4 Others
- 8.5 North America Antibody Contract Manufacturing Market (2018-2034) by Country
- 8.5.1 United States of America
- 8.5.1.1 United States of America Antibody Contract Manufacturing Market (2018-2034) by Product
- 8.5.2 Canada
- 8.5.2.1 Canada Antibody Contract Manufacturing Market (2018-2034) by Product
- 9 Europe Antibody Contract Manufacturing Market (218-2034)
- 9.1 Europe Antibody Contract Manufacturing Market (2018-2034) by Product
- 9.1.1 Market Overview
- 9.1.2 Monoclonal Antibodies
- 9.1.3 Polyclonal Antibodies
- 9.1.4 Others
- 9.2 Europe Antibody Contract Manufacturing Market (2018-2034) by Source
- 9.2.1 Market Overview
- 9.2.2 Mammalian
- 9.2.3 Microbial
- 9.3 Europe Antibody Contract Manufacturing Market (2018-2034) by Therapeutic Area
- 9.3.1 Market Overview
- 9.3.2 Cardiology
- 9.3.3 Oncology
- 9.3.4 Infectious Diseases
- 9.3.5 Immune Disorders
- 9.3.6 Neurology
- 9.3.7 Others
- 9.4 Europe Antibody Contract Manufacturing Market (2018-2034) by End User
- 9.4.1 Market Overview
- 9.4.2 Biopharmaceutical and Pharmaceutical Companies
- 9.4.3 Research Laboratories
- 9.4.4 Others
- 9.5 Europe Antibody Contract Manufacturing Market (2018-2034) by Country
- 9.5.1 United Kingdom
- 9.5.1.1 United Kingdom Antibody Contract Manufacturing Market (2018-2034) by Product
- 9.5.2 Germany
- 9.5.2.1 Germany Antibody Contract Manufacturing Market (2018-2034) by Product
- 9.5.3 France
- 9.5.3.1 France Antibody Contract Manufacturing Market (2018-2034) by Product
- 9.5.4 Italy
- 9.5.4.1 Italy Antibody Contract Manufacturing Market (2018-2034) by Product
- 9.5.5 Others
- 10 Asia Pacific Antibody Contract Manufacturing Market (218-2034)
- 10.1 Asia Pacific Antibody Contract Manufacturing Market (2018-2034) by Product
- 10.1.1 Market Overview
- 10.1.2 Monoclonal Antibodies
- 10.1.3 Polyclonal Antibodies
- 10.1.4 Others
- 10.2 Asia Pacific Antibody Contract Manufacturing Market (2018-2034) by Source
- 10.2.1 Market Overview
- 10.2.2 Mammalian
- 10.2.3 Microbial
- 10.3 Asia Pacific Antibody Contract Manufacturing Market (2018-2034) by Therapeutic Area
- 10.3.1 Market Overview
- 10.3.2 Cardiology
- 10.3.3 Oncology
- 10.3.4 Infectious Diseases
- 10.3.5 Immune Disorders
- 10.3.6 Neurology
- 10.3.7 Others
- 10.4 Asia Pacific Antibody Contract Manufacturing Market (2018-2034) by End User
- 10.4.1 Market Overview
- 10.4.2 Biopharmaceutical and Pharmaceutical Companies
- 10.4.3 Research Laboratories
- 10.4.4 Others
- 10.5 Asia Pacific Antibody Contract Manufacturing Market (2018-2034) by Country
- 10.5.1 China
- 10.5.1.1 China Antibody Contract Manufacturing Market (2018-2034) by Product
- 10.5.2 Japan
- 10.5.2.1 Japan Antibody Contract Manufacturing Market (2018-2034) by Product
- 10.5.3 India
- 10.5.3.1 India Antibody Contract Manufacturing Market (2018-2034) by Product
- 10.5.4 ASEAN
- 10.5.4.1 ASEAN Antibody Contract Manufacturing Market (2018-2034) by Product
- 10.5.5 Australia
- 10.5.5.1 Australia Antibody Contract Manufacturing Market (2018-2034) by Product
- 10.5.6 Others
- 11 Latin America Antibody Contract Manufacturing Market (218-2034)
- 11.1 Latin America Antibody Contract Manufacturing Market (2018-2034) by Product
- 11.1.1 Market Overview
- 11.1.2 Monoclonal Antibodies
- 11.1.3 Polyclonal Antibodies
- 11.1.4 Others
- 11.2 Latin America Antibody Contract Manufacturing Market (2018-2034) by Source
- 11.2.1 Market Overview
- 11.2.2 Mammalian
- 11.2.3 Microbial
- 11.3 Latin America Antibody Contract Manufacturing Market (2018-2034) by Therapeutic Area
- 11.3.1 Market Overview
- 11.3.2 Cardiology
- 11.3.3 Oncology
- 11.3.4 Infectious Diseases
- 11.3.5 Immune Disorders
- 11.3.6 Neurology
- 11.3.7 Others
- 11.4 Latin America Antibody Contract Manufacturing Market (2018-2034) by End User
- 11.4.1 Market Overview
- 11.4.2 Biopharmaceutical and Pharmaceutical Companies
- 11.4.3 Research Laboratories
- 11.4.4 Others
- 11.5 Latin America Antibody Contract Manufacturing Market (2018-2034) by Country
- 11.5.1 Brazil
- 11.5.1.1 Brazil Antibody Contract Manufacturing Market (2018-2034) by Product
- 11.5.2 Argentina
- 11.5.2.1 Argentina Antibody Contract Manufacturing Market (2018-2034) by Product
- 11.5.3 Mexico
- 11.5.3.1 Mexico Antibody Contract Manufacturing Market (2018-2034) by Product
- 11.5.4 Others
- 12 Middle East and Africa Antibody Contract Manufacturing Market (218-2034)
- 12.1 Middle East and Africa Antibody Contract Manufacturing Market (2018-2034) by Product
- 12.1.1 Market Overview
- 12.1.2 Monoclonal Antibodies
- 12.1.3 Polyclonal Antibodies
- 12.1.4 Others
- 12.2 Middle East and Africa Antibody Contract Manufacturing Market (2018-2034) by Source
- 12.2.1 Market Overview
- 12.2.2 Mammalian
- 12.2.3 Microbial
- 12.3 Middle East and Africa Antibody Contract Manufacturing Market (2018-2034) by Therapeutic Area
- 12.3.1 Market Overview
- 12.3.2 Cardiology
- 12.3.3 Oncology
- 12.3.4 Infectious Diseases
- 12.3.5 Immune Disorders
- 12.3.6 Neurology
- 12.3.7 Others
- 12.4 Middle East and Africa Antibody Contract Manufacturing Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Biopharmaceutical and Pharmaceutical Companies
- 12.4.3 Research Laboratories
- 12.4.4 Others
- 12.5 Middle East and Africa Antibody Contract Manufacturing Market (2018-2034) by Country
- 12.5.1 Saudi Arabia
- 12.5.1.1 Saudi Arabia Antibody Contract Manufacturing Market (2018-2034) by Product
- 12.5.2 United Arab Emirates
- 12.5.2.1 United Arab Emirates Antibody Contract Manufacturing Market (2018-2034) by Product
- 12.5.3 Nigeria
- 12.5.3.1 Nigeria Antibody Contract Manufacturing Market (2018-2034) by Product
- 12.5.4 South Africa
- 12.5.4.1 South Africa Antibody Contract Manufacturing Market (2018-2034) by Product
- 12.5.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 14 Grants Analysis
- 14.1 Analysis by Year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Drug Class of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Strategic Initiatives
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Drug Class of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Market Share Analysis, By Region (Top 5 Companies)
- 17.1.1 Market Share Analysis: Global
- 17.1.2 Market Share Analysis: North America
- 17.1.3 Market Share Analysis: Europe
- 17.1.4 Market Share Analysis: Asia Pacific
- 17.1.5 Market Share Analysis: Others
- 17.2 Lonza
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Company News and Development
- 17.2.5 Certifications
- 17.3 Samsung Biologics Co., Ltd.
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Company News and Development
- 17.3.5 Certifications
- 17.4 WuXi Biologics (Cayman) Inc.
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Company News and Development
- 17.4.5 Certifications
- 17.5 Charles River Laboratories
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Company News and Development
- 17.5.5 Certifications
- 17.6 FUJIFILM Holdings Corporation
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Company News and Development
- 17.6.5 Certifications
- 17.7 AGC Biologics
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Company News and Development
- 17.7.5 Certifications
- 17.8 Cytovance Biologics, Inc.
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Company News and Development
- 17.8.5 Certifications
- 17.9 Emergent BioSolutions
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Company News and Development
- 17.9.5 Certifications
- 17.10 Thermo Fisher Scientific Inc.
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Company News and Development
- 17.10.5 Certifications
- 17.11 Labcorp Drug Development
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Company News and Development
- 17.11.5 Certifications
- 17.12 Catalent, Inc.
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Company News and Development
- 17.12.5 Certifications
- 17.13 Boehringer Ingelheim Biopharmaceuticals GmbH
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Company News and Development
- 17.13.5 Certifications
- 18 Global Antibody Contract Manufacturing Market – Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
